Dual-Targeted Galactose-TPP Dendrimers Modulate Mitochondrial Function and Downstream Outcomes in Hepatocellular Carcinoma
Biomacromolecules · 09.11.2026 · 27 (11) · 7080-7102
DOI: 10.1021/acs.biomac.6c00654 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomacromolecules, online erschienen am 12.10.2026. Verfasst von Vikrantvir Jain und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan48104, United States. Hauptthemen laut MEDLINE: Galactose, Liver Neoplasms, Sorafenib, Carcinoma, Hepatocellular. Die Arbeit nennt 78 Literaturangaben.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) remains therapeutically challenging. Sorafenib, the standard first-line therapy for advanced HCC, suffers from poor aqueous solubility, non-specific biodistribution, dose-limiting toxicities, and the emergence of mitochondrial-mediated resistance. Here, we engineered a dual-targeted dendrimer nanoplatform that integrates hepatocyte-selective recognition with organelle-specific drug delivery. Galactose-functionalized Gal24 dendrimers were designed to engage the asialoglycoprotein receptor, while triphenylphosphonium enabled mitochondrial localization. Sorafenib was conjugated through CuAAC click chemistry to generate Gal24-TPP-Sora, which exhibited enhanced aqueous solubility, colloidal stability, and mitochondrial accumulation. In Hep3B cells, Gal24-TPP-Sora induced profound mitochondrial dysfunction, evidenced by elevated superoxide generation, ATP depletion, membrane depolarization, and enhanced apoptosis, accompanied by marked inhibition of proliferation, migration, and clonogenic survival. These effects surpassed free sorafenib and non-mitochondrial controls while preserving cytocompatibility and hemocompatibility. Collectively, this work establishes a precision nanotherapeutic strategy that couples receptor-mediated targeting with the mitochondrial intervention to potentiate sorafenib activity and overcome key therapeutic limitations in advanced HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan48104, United States.
- Department of Chemistry, College of Arts and Sciences, Washington State University, Pullman, Washington99164, United States.
ORCID-Profile: Anjali Sharma
Zitieren
APA
Jain, V., Dar, A. I., Biswas, A., Pulukuri, A. J., Sharma, R., & Sharma, A. (2026). Dual-Targeted Galactose-TPP Dendrimers Modulate Mitochondrial Function and Downstream Outcomes in Hepatocellular Carcinoma. Biomacromolecules, 27(11), 7080-7102. https://doi.org/10.1021/acs.biomac.6c00654
Vancouver
Jain V, Dar AI, Biswas A, Pulukuri AJ, Sharma R, Sharma A. Dual-Targeted Galactose-TPP Dendrimers Modulate Mitochondrial Function and Downstream Outcomes in Hepatocellular Carcinoma. Biomacromolecules. 2026;27(11):7080-7102. doi:10.1021/acs.biomac.6c00654
BibTeX
@article{Jain2026,
author = {Jain, Vikrantvir and Dar, Aqib Iqbal and Biswas, Ananya and Pulukuri, Anunay James and Sharma, Rishi and Sharma, Anjali},
title = {Dual-Targeted Galactose-TPP Dendrimers Modulate Mitochondrial Function and Downstream Outcomes in Hepatocellular Carcinoma},
journal = {Biomacromolecules},
year = {2026},
volume = {27},
number = {11},
pages = {7080--7102},
doi = {10.1021/acs.biomac.6c00654}
}
EUVIMED